| The oncogenic TEL/PDGFR beta fusion protein induces cell death through JNK/SAPK pathway. | None |
| an activating point mutation results in a deregulated PDGFRbeta with oncogenic predisposition | None |
| The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors. | None |
| Critical role of the platelet-derived growth factor receptor (PDGFR) beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein. | None |